Fingolimod for relapsing‐remitting multiple sclerosis
L La Mantia, I Tramacere, B Firwana… - Cochrane Database …, 2016 - cochranelibrary.com
L La Mantia, I Tramacere, B Firwana, I Pacchetti, R Palumbo, G Filippini
Cochrane Database of Systematic Reviews, 2016•cochranelibrary.comBackground Fingolimod was approved in 2010 for the treatment of patients with the
relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the
frequency of exacerbations and to delay disability worsening. Issues on its safety and
efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.
Objectives To assess the safety and benefit of fingolimod versus placebo, or other disease‐
modifying drugs (DMDs), in reducing disease activity in people with relapsing‐remitting …
relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the
frequency of exacerbations and to delay disability worsening. Issues on its safety and
efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.
Objectives To assess the safety and benefit of fingolimod versus placebo, or other disease‐
modifying drugs (DMDs), in reducing disease activity in people with relapsing‐remitting …
Background
Fingolimod was approved in 2010 for the treatment of patients with the relapsing‐remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.
Objectives
To assess the safety and benefit of fingolimod versus placebo, or other disease‐modifying drugs (DMDs), in reducing disease activity in people with relapsing‐remitting multiple sclerosis (RRMS).
cochranelibrary.com
以上显示的是最相近的搜索结果。 查看全部搜索结果